Saw Palmetto Dosage: What Prostate Trials Actually Used

Amounts used in saw palmetto research

Figures are amounts reported in the cited sources, not a personal recommendation. Your own amount depends on your health, medicines and blood work.

Why 320 mg is the number on nearly every label

The 320 mg per day figure is not a manufacturer's invention. It is the amount that European lipidosterolic extracts were standardised to decades ago, and it became the comparator used in the clinical literature that followed.

Because trials converged on it, supplement labels converged on it too. That consistency is genuinely useful: when you compare products, you are usually comparing the same daily amount of a similar extract, so the meaningful differences are extract type, standardisation and manufacturing quality rather than dose.

Splitting it as 160 mg twice a day is equally common and was used in several trials. There is no evidence that one schedule outperforms the other.

• 320 mg per day of lipidic extract is the trial standard
• 160 mg twice daily was used interchangeably
• Whole berry powder is not the same preparation
• Higher doses were tested and did not work better

What the large trials found

The STEP trial randomised men with moderate-to-severe BPH symptoms to 320 mg of saw palmetto extract or placebo for a year and found no difference in symptom scores, urinary flow rate, prostate size or quality of life.

CAMUS went further: it escalated the dose to 640 mg and then 960 mg per day over 72 weeks, testing directly whether the earlier null results were a dosing problem. They were not — symptom scores improved similarly in both groups.

Earlier positive results came largely from smaller, shorter and less rigorously blinded studies. A Cochrane review that pooled the literature concluded saw palmetto did not improve urinary symptoms or flow measures compared with placebo, even at double and triple the usual dose.

This is a case where more evidence made the picture clearer rather than murkier, and the direction it moved in was toward no effect.

Extract type matters more than milligrams

Serenoa repens products vary widely. The trials used lipidosterolic extracts prepared with hexane or supercritical CO2, standardised to roughly 85–95% fatty acids and sterols. Dried berry capsules, tinctures and teas deliver a different chemical profile entirely.

If a label lists '320 mg saw palmetto berry powder', that is not the preparation tested in the trials, whatever the number says. Look instead for a standardised extract with the fatty acid content stated.

None of this makes the extract effective — it simply means that when comparing products you should compare like with like.

Safety, PSA testing and the surgical question

Saw palmetto is generally well tolerated in trials. The reported adverse effects are mostly mild and gastrointestinal — nausea, abdominal discomfort, diarrhea — with headache reported occasionally.

Rare cases of liver injury and pancreatitis have been described in the literature, which is worth knowing but sits against very widespread use.

Unlike finasteride, saw palmetto has not been shown in trials to meaningfully lower PSA, so it is less likely to mask a rising PSA reading. Even so, anyone using it should tell the clinician ordering the test.

Because saw palmetto may affect platelet function, stopping it ahead of planned surgery is a common precaution, and anyone taking anticoagulants should raise it with their prescriber.

How to think about it if you already take it

Urinary symptoms are a reason to be assessed, not a reason to self-treat indefinitely. BPH, prostatitis, infection and prostate cancer can produce overlapping symptoms, and the supplement route delays the part that matters.

If you take saw palmetto and feel it helps, that experience is real even when the trial evidence is null — but it is worth tracking symptom scores over time rather than relying on impressions, and worth reviewing with a clinician who knows you take it.

Track it alongside anything else you use for prostate or urinary symptoms so interactions and overlaps stay visible.

What the published studies found

Each entry below links straight to the paper or the health authority page so you can read the original rather than take our word for it.

• Barry MJ et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms (CAMUS randomized trial). JAMA. 2011.

  Randomised, double-blind, placebo-controlled trial, 369 men, 72 weeks

  Escalating doses of 320, 640 and 960 mg per day produced no greater improvement in AUA Symptom Index scores than placebo.

• Bent S et al. Saw palmetto for benign prostatic hyperplasia (STEP trial). N Engl J Med. 2006.

  Randomised, double-blind, placebo-controlled trial, 225 men, one year

  320 mg per day of saw palmetto extract did not improve symptom scores, peak urinary flow, prostate size or quality of life versus placebo.

• Tacklind J et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews.

  Systematic review and meta-analysis of randomised trials

  Saw palmetto did not improve urinary symptom scores or flow measures compared with placebo, including at double and triple the usual dose.

Side effects reported in the literature

Summarized from NCCIH — Saw Palmetto. Report anything unexpected to your own doctor or pharmacist.

Interactions to check with a pharmacist

This is not a complete interaction list. Check your own medicines with a pharmacist before combining anything.

Frequently asked questions

Keep reading

• BPH natural support: what the evidence shows
• Saw palmetto vs beta-sitosterol
• Zinc dosage guide

Sources

1. National Center for Complementary and Integrative Health. Saw Palmetto.
2. Barry MJ et al. CAMUS randomized trial. JAMA. 2011.
3. Bent S et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006.
4. Tacklind J et al. Serenoa repens for benign prostatic hyperplasia. Cochrane.